Luminex received FDA Emergency Use Authorization for COVID-19 antibody test
On Jul. 20, 2020, Luminex announced the FDA had issued an Emergency Use Authorization for the company’s xMAPï¾®…
HDT BIOï¾’s COVID-19 vaccine candidate HDT-301 induced neutralizing antibody responses after single injection
On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they…
HDT Bio partnered with Gennova Biopharmaceuticals to bring COVID-19 vaccine to human trials
On Jul. 19, 2020, HDT Bio announced co-development efforts with Gennova Biopharmaceuticals to start evaluating HDT-301, a COVID-19…
Novartis launched first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
On Jul. 16, 2020, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC;…
RedHill Biopharma received approval for phase 2/3 COVID-19 study in Russia
On Jul. 16, 2020, RedHill Biopharma announced approval from the Ministry of Health of the Russian Federation for…
Heron Therapeutics announced initiation of phase 2 clinical study of CINVANTIï¾® for treatment of COVID-19
On Jul. 16, 2020, Heron Therapeutics announced initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating…
Codex DNA released new synthetic SARS-CoV-2 genome for COVID-19 vaccine and therapeutic research
On Jul. 16, 2020, Codex DNA announced the release of a new synthetic SARS-CoV-2 genome developed to accelerate…
Tonix Pharma announced research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Jul. 16, 2020, Tonix Pharmaceuticals announced it had entered into a research collaboration and option agreement with…
Atossa Therapeutics contracted for clinical study of AT-301 nasal spray for treating COVID-19
On Jul. 16, 2020, Atossa Therapeutics announced that it has contracted with Avance Clinical to conduct a clinical…
WHO and UNICEF warn of a decline in vaccinations during COVID-19
On Jul. 14, 2020, the WHO and UNICEF warned of an alarming decline in the number of children…
More than 150 countries engaged in COVID-19 vaccine global access facility
On Jul. 15, 2020, seventy-five countries submitted expressions of interest to protect their populations and those of other…
BIOFIRE respiratory panel 21 plus with SARS-CoV-2 was CE marked
On Jul. 15, 2020, bioMerieux announced that the BIOFIRE Respiratory Panel 2.1 plus (RP2.1plus) was CE marked. The…
COVID-19 antibody tests evaluated as diagnostic test in low-resource settings
On Jul. 15, 2020, scientists at Washington University School of Medicine in St. Louis reported they had joined…
BD announced purchase agreement with U.S. Dept of HHS to expand access to rapid point-of-care testing for COVID-19
On Jul. 15, 2020, BD (Becton, Dickinson) announced a commitment from the U.S. Department of Health and Human…
BioAegis received approval to proceed with phase 2 trial of its gelsolin COVID-19 treatment
On Jul. 15, 2020, BioAegis Therapeutics announced that it received regulatory clearance from The Spanish Agency for Medicines…
Tevogen Bio announced steps toward proprietary T Cell therapy for development of bivalent vaccine for COVID-19 and influenza
On Jul. 15, 2020, Tevogen Bio announced its intention to evaluate its proprietary antigen-specific T cell technology as…
Philanthropic gifts funded COVID-19 pilot research projects at Einstein and Montefiore
On Jul. 15, 2020, four Einstein and Montefiore research teams received pilot funding from Einsteinï¾’s Office of the…
AXIM Biotechnologies unveiled first-in-class COVID-19 rapid diagnostic test for neutralizing antibodies
On Jul. 15, 2020, AXIM Biotechnologies announced the development of NeuCovixTM, a rapid diagnostic test measuring levels of…
Cleveland Clinic researchers Identified genetic factors that may Influence COVID-19 susceptibility
On Jul. 15, 2020, A new Cleveland Clinic study identified genetic factors that may influence susceptibility to COVID-19….
Atossa Therapeutics announced successful in vitro testing of nasal spray formulation with SARS-CoV-2
On Jul. 15, 2020, Atossa Therapeutics announced successful results from in vitro testing of AT-301, Atossa’s proprietary COVID-19…
Akebia announced initiation of investigator-sponsored study evaluating vadadustat for prevention and treatment of ARDS in patients with COVID-19
On Jul. 14, 2020, Akebia Therapeutics announced the initiation of an investigator-sponsored study evaluating the use of vadadustat,…
Experimental COVID-19 vaccine safe, generated immune response
On Jul. 14, 2020, an investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus…
CDC called on Americans to wear masks to prevent COVID-19 spread
On Jul. 14, 2020, in an editorial published in the Journal of the American Medical Association (JAMA), the…
Experimental Coronavirus vaccine is safe and produced immune response
On Jul. 14, 2020, NIH researchers reported early results from the first COVID-19 vaccine candidate tested in people…
CDC called on Americans to wear masks to prevent COVID-19 spread
On Jul. 14, 2020, in an editorial published in the Journal of the American Medical Association (JAMA), the…
HKUMed researchers mined immunogenic information from SARS-CoV-2 for rational design of vaccine against SARS-CoV-2
On Jul. 14, 2020, researchers at the The University of Hong Kong (HKUMed) collaborated with researchers at the…
Fosun announced COVID-19 vaccine product received acceptance notice of clinical trial application by NMPA
On Jul. 14, 2020, Shanghai Fosun Pharmaceutical announced it had received the acceptance notice of clinical trial application…
Rigel announces investigator-sponsored trial of fostamatinib in patients with COVID-19 pneumonia
On Jul. 14, 2020, Rigel Pharmaceuticals announced the initiation of an investigator-sponsored tria being conducted by Imperial College…
Dynavax announced first participants dosed in phase 1 clinical evaluating Medicagoï¾’s COVID-19 vaccine candidate
On Jul. 14, 2020, Dynavax Technologies announced that the first participants have been dosed in the Phase 1…
Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Jul. 14, 2020, Moderna announced the publication of an interim analysis of the open-label Phase 1 study…